Latest news with #Epidemiology
Globe and Mail
12-08-2025
- Health
- Globe and Mail
PharmaIN, AstraZeneca plc, Pfizer Inc., Novartis AG, Baxter International Inc., Becton, Dickinson and Company
The Key Ascites Companies in the market include - PharmaIN, AstraZeneca plc, Pfizer Inc., Novartis AG, Baxter International Inc., Becton, Dickinson and Company, F. Hoffmann-La Roche AG, Merit Medical Systems Inc., Neovii Pharmaceuticals AG, GI Supply, BioVie, Ocelot Bio, Movetis, Sanofi, Otsuka Beijing Research Institute, Grifols Therapeutics LLC, Norgine, and others. DelveInsight's 'Ascites Market Insights, Epidemiology, and Market Forecast-2034″ report offers an in-depth understanding of the Ascites, historical and forecasted epidemiology as well as the Ascites market trends in the United States, EU4 (Germany, Spain, Italy, France, and United Kingdom) and Japan. Some of the key facts of the Ascites Market Report: The Ascites market size is anticipated to grow with a significant CAGR during the study period (2020-2034) In November 2024, Pharmanovia, an international pharmaceutical company specializing in commercializing innovative therapies and enhancing the lifecycle of established medicines, announced the expansion of its oncology portfolio through a new licensing agreement for catumaxomab, aimed at treating malignant ascites. In 2023, the US ascites market size attributed to cirrhosis was valued at over USD 800 million, with projections indicating growth throughout the forecast period (2024–2034). In 2023, the market size for diuretics used in the treatment of ascites caused by cirrhosis in the US was estimated to be approximately USD 140 million. In 2023, the US had the highest number of ascites cases caused by cirrhosis among the 7MM, exceeding 152,000 cases. This figure is expected to rise throughout the forecast period (2024-2034). In 2023, breast cancer contributed the highest number of ascites cases caused by malignancies in the US, with approximately 13,000 cases, followed by colorectal cancer. In the US, severity-specific cases of Grade II and III ascites totaled approximately 125,000 in 2023. Key Ascites Companies: PharmaIN, AstraZeneca plc, Pfizer Inc., Novartis AG, Baxter International Inc., Becton, Dickinson and Company, F. Hoffmann-La Roche AG, Merit Medical Systems Inc., Neovii Pharmaceuticals AG, GI Supply, BioVie, Ocelot Bio, Movetis, Sanofi, Otsuka Beijing Research Institute, Grifols Therapeutics LLC, Norgine, and others Key Ascites Therapies: PHIN-214, BIV201 (Terlipressin), OCE-205, catumaxomab, M0002, satavaptan (SR121463B), Tolvaptan, Albumin, Rifaximin, and others The Ascites market is expected to surge due to the disease's increasing prevalence and awareness during the forecast period. Furthermore, launching various multiple-stage Ascites pipeline products will significantly revolutionize the Ascites market dynamics. Ascites Overview A surplus of intraperitoneal fluid is referred to as ascites (hydroperitoneum is a rare synonym). Ascites is a disorder where fluid builds up in the abdominal cavities. Ascites may be painful in extreme cases. Get a Free sample for the Ascites Market Report Ascites Epidemiology The epidemiology section provides insights into the historical, current, and forecasted epidemiology trends in the seven major countries (7MM) from 2020 to 2034. It helps to recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. The epidemiology section also provides a detailed analysis of the diagnosed patient pool and future trends. Ascites Epidemiology Segmentation: The Ascites market report proffers epidemiological analysis for the study period 2020–2034 in the 7MM segmented into: Download the report to understand which factors are driving Ascites epidemiology trends @ Ascites Epidemiology Forecast Ascites Drugs Uptake and Pipeline Development Activities The drugs uptake section focuses on the rate of uptake of the potential drugs recently launched in the Ascites market or expected to get launched during the study period. The analysis covers Ascites market uptake by drugs, patient uptake by therapies, and sales of each drug. Moreover, the therapeutics assessment section helps understand the drugs with the most rapid uptake and the reasons behind the maximal use of the drugs. Additionally, it compares the drugs based on market share. The report also covers the Ascites Pipeline Development Activities. It provides valuable insights about different therapeutic candidates in various stages and the key companies involved in developing targeted therapeutics. It also analyzes recent developments such as collaborations, acquisitions, mergers, licensing patent details, and other information for emerging therapies. Ascites Therapies and Key Companies Discover more about therapies set to grab major Ascites market share @ Ascites Treatment Market Ascites Market Strengths The rise in the patient population of underlying conditions of ascites such as liver cirrhosis, alcoholism, kidney or heart failure, malignancy, etc. might contribute to an increase in the patient population of ascites Ascites Market Opportunities Limited approved, and emerging therapies in the pipeline offer a great opportunity for the investment and development of novel therapies Scope of the Ascites Market Report Study Period: 2020–2034 Coverage: 7MM [The United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan] Key Ascites Companies: PharmaIN, AstraZeneca plc, Pfizer Inc., Novartis AG, Baxter International Inc., Becton, Dickinson and Company, F. Hoffmann-La Roche AG, Merit Medical Systems Inc., Neovii Pharmaceuticals AG, GI Supply, BioVie, Ocelot Bio, Movetis, Sanofi, Otsuka Beijing Research Institute, Grifols Therapeutics LLC, Norgine, and others Key Ascites Therapies: PHIN-214, BIV201 (Terlipressin), OCE-205, catumaxomab, M0002, satavaptan (SR121463B), Tolvaptan, Albumin, Rifaximin, and others Ascites Therapeutic Assessment: Ascites current marketed and Ascites emerging therapies Ascites Market Dynamics: Ascites market drivers and Ascites market barriers Competitive Intelligence Analysis: SWOT analysis, PESTLE analysis, Porter's five forces, BCG Matrix, Market entry strategies Table of Contents 1. Ascites Market Report Introduction 2. Executive Summary for Ascites 3. SWOT analysis of Ascites 4. Ascites Patient Share (%) Overview at a Glance 5. Ascites Market Overview at a Glance 6. Ascites Disease Background and Overview 7. Ascites Epidemiology and Patient Population 8. Country-Specific Patient Population of Ascites 9. Ascites Current Treatment and Medical Practices 10. Ascites Unmet Needs 11. Ascites Emerging Therapies 12. Ascites Market Outlook 13. Country-Wise Ascites Market Analysis (2020–2034) 14. Ascites Market Access and Reimbursement of Therapies 15. Ascites Market Drivers 16. Ascites Market Barriers 17. Ascites Appendix 18. Ascites Report Methodology 19. DelveInsight Capabilities 20. Disclaimer 21. About DelveInsight About DelveInsight DelveInsight is a leading Healthcare Business Consultant, and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance. It also offers Healthcare Consulting Services, which benefits in market analysis to accelerate the business growth and overcome challenges with a practical approach. Media Contact Company Name: DelveInsight Contact Person: Gaurav Bora Email: Send Email Phone: +14699457679 Address: 304 S. Jones Blvd #2432 City: Las Vegas State: NV Country: United States Website:
Globe and Mail
07-08-2025
- Business
- Globe and Mail
Dendreon Pharma, Candel Therapeutics, GlaxoSmithKline, Merck, Aduro Biotech, Astrazeneca Plc, Dendreon
The Key Cancer Vaccines Companies in the market include - Dendreon Pharma, Candel Therapeutics, GlaxoSmithKline, Merck, Aduro Biotech, Astrazeneca Plc, Dendreon, Astellas Pharma Inc, Sanofi, , Sanpower Group and CSL Ltd., Northwest Biotherapeutics, IO Biotech, Immunomic Therapeutics, Evaxion Biotech, Candel Therapeutics, Aston Sci, Evaxion Biotech, and others. DelveInsight's 'Cancer Vaccines Market Insights, Epidemiology, and Market Forecast-2034″ report offers an in-depth understanding of the Cancer Vaccines, historical and forecasted epidemiology as well as the Cancer Vaccines market trends in the United States, EU4 (Germany, Spain, Italy, France) the United Kingdom and Japan. Some of the key facts of the Cancer Vaccines Market Report: The Cancer Vaccines market size is anticipated to grow with a significant CAGR during the study period (2020-2034) In March 2025, Everest Medicines administered the first dose of EVM16, its personalized mRNA cancer vaccine, to a participant in the first-in-human (FIH) trial, EVM16CX01. In February 2025, In a Phase I investigator-led trial, all nine patients who received a personalized kidney cancer vaccine developed anti-cancer immune responses after undergoing tumor removal surgery. Researchers at the Dana-Farber Cancer Institute in the U.S. administered the NeoVax personalized cancer vaccine to patients with stage III or IV clear cell renal cell carcinoma (ccRCC) following their surgeries. In August 2024, BioNTech launched global clinical trials for BNT116, an mRNA vaccine being developed as a potential treatment for non-small cell lung cancer (NSCLC). The vaccine utilizes the same mRNA technology that played a crucial role in the development of Covid-19 vaccines. In February 2024, A cancer vaccine trial initiated by Moderna commenced in the UK, with researchers optimistic about ushering in a new era of treatments. In 2023, the estimated number of incident cases of non-small cell lung cancer (NSCLC) in the US was approximately 200,000. Uveal melanoma impacts approximately 500 to 600 individuals annually in the UK. The cancer vaccines market features a robust and expanding pipeline with candidates such as IO102-IO103 (IO Biotech), CAN-2409 (Candel Therapeutics), mRNA-4157 (V940) combined with KEYTRUDA (Merck and Moderna), PDClung01 (PDCline Pharma/LG Chem), and LB-LR1109 (LG Chem and AVEO Oncology). These vaccines target a variety of cancers, including non-small cell lung cancer (NSCLC), colorectal cancer, glioblastoma, melanoma, breast cancer, and more. Key Cancer Vaccines Companies: Dendreon Pharma, Candel Therapeutics, GlaxoSmithKline, Merck, Aduro Biotech, Astrazeneca Plc, Dendreon, Astellas Pharma Inc, Sanofi, , Sanpower Group and CSL Ltd., Northwest Biotherapeutics, IO Biotech, Immunomic Therapeutics, Evaxion Biotech, Candel Therapeutics, Aston Sci, Evaxion Biotech, and others Key Cancer Vaccines Therapies: DCVax-L, IO102-IO103, ITI-1000, EVX-01, CAN-2409, AST-301, EVX-02, and others Several vaccine constructions have been tested for anticancer therapy. In each case, these vaccines are designed to present tumor-associated peptides integrated with MHC molecules to cognate receptors on B or T lymphocytes and stimulate their activation, maturation, and proliferation The Cancer Vaccines market is expected to surge due to the disease's increasing prevalence and awareness during the forecast period. Furthermore, launching various multiple-stage Cancer Vaccines pipeline products will significantly revolutionize the Cancer Vaccines market dynamics. Cancer Vaccines Overview Cancer vaccines are a type of immunotherapy designed to stimulate the body's immune system to recognize and attack cancer cells. Unlike traditional vaccines, which prevent infectious diseases by priming the immune system to recognize and fight off specific pathogens (such as viruses or bacteria), cancer vaccines are used to treat existing cancer or to prevent cancer recurrence. Cancer Vaccines Epidemiology The epidemiology section provides insights into the historical, current, and forecasted epidemiology trends in the seven major countries (7MM) from 2020 to 2034. It helps to recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. The epidemiology section also provides a detailed analysis of the diagnosed patient pool and future trends. Cancer Vaccines Epidemiology Segmentation: The Cancer Vaccines market report proffers epidemiological analysis for the study period 2020–2034 in the 7MM segmented into: Cancer Vaccines Drugs Uptake and Pipeline Development Activities The drugs uptake section focuses on the rate of uptake of the potential drugs recently launched in the Cancer Vaccines market or expected to get launched during the study period. The analysis covers Cancer Vaccines market uptake by drugs, patient uptake by therapies, and sales of each drug. Moreover, the therapeutics assessment section helps understand the drugs with the most rapid uptake and the reasons behind the maximal use of the drugs. Additionally, it compares the drugs based on market share. The report also covers the Cancer Vaccines Pipeline Development Activities. It provides valuable insights about different therapeutic candidates in various stages and the key companies involved in developing targeted therapeutics. It also analyzes recent developments such as collaborations, acquisitions, mergers, licensing patent details, and other information for emerging therapies. Cancer Vaccines Therapies and Key Companies Cancer Vaccines Market Strengths Advancements in computational and bioinformatics platforms and several other R&D practices enable the development of cancer neoantigen vaccination strategies Neoantigen-based Personalized Cancer Therapeutic Vaccines like Vigil and Tedopi along with few others can stimulate immune responses to checkpoint inhibitors even in patients that have previously failed conventional treatment regimes, thereby, addressing potential unmet needs of the market Cancer Vaccines Market Opportunities Rising incidence of cancer will provide a larger window of opportunity for these novel vaccines Recurrence is very common in cancers even after proper treatment. This opens up new window for Neoantigen-based Personalized Cancer Therapeutic Vaccines to dominate the treatment regime Scope of the Cancer Vaccines Market Report Table of Contents 1. Cancer Vaccines Market Report Introduction 2. Executive Summary for Cancer Vaccines 3. SWOT analysis of Cancer Vaccines 4. Cancer Vaccines Patient Share (%) Overview at a Glance 5. Cancer Vaccines Market Overview at a Glance 6. Cancer Vaccines Disease Background and Overview 7. Cancer Vaccines Epidemiology and Patient Population 8. Country-Specific Patient Population of Cancer Vaccines 9. Cancer Vaccines Current Treatment and Medical Practices 10. Cancer Vaccines Unmet Needs 11. Cancer Vaccines Emerging Therapies 12. Cancer Vaccines Market Outlook 13. Country-Wise Cancer Vaccines Market Analysis (2020–2034) 14. Cancer Vaccines Market Access and Reimbursement of Therapies 15. Cancer Vaccines Market Drivers 16. Cancer Vaccines Market Barriers 17. Cancer Vaccines Appendix 18. Cancer Vaccines Report Methodology 19. DelveInsight Capabilities 20. Disclaimer 21. About DelveInsight About DelveInsight DelveInsight is a leading Healthcare Business Consultant, and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance. It also offers Healthcare Consulting Services, which benefits in market analysis to accelerate the business growth and overcome challenges with a practical approach. Media Contact Company Name: DelveInsight Contact Person: Gaurav Bora Email: Send Email Phone: +14699457679 Address: 304 S. Jones Blvd #2432 City: Las Vegas State: NV Country: United States Website:
Fast Company
05-08-2025
- Health
- Fast Company
Why urban designers should think like doctors
What if buildings and neighborhoods were planned with health and climate risks in mind, just like businesses use financial data to guide their decisions? What if public health and real estate weren't at odds, but instead coauthors of a healthier, more equitable urban future? That's the bold premise of Architectural Epidemiology, a new book that offers a radical rethinking of the relationship between place and health. Written by architect and public health expert Adele Houghton and Dr. Carlos Castillo-Salgado, an epidemiologist, the book introduces a place-based framework for aligning real estate investment with public health goals—using the tools of epidemiology to guide design decisions that affect buildings and the way they engage the surrounding city. At its core, architectural epidemiology is not a metaphor. It's a methodology. Diagnosing places like patients Just as a doctor might diagnose a patient based on symptoms and environmental exposures, Houghton and Castillo-Salgado's framework helps designers, developers, and policymakers diagnose the health of a place. The process begins by gathering publicly available health and climate data—rates of asthma, heat exposure, housing-cost burden, chronic illness, and more—and dialing into the specific needs of any real estate project boundary. These place-based insights then inform customized development strategies tailored to local needs. This isn't a one-size-fits-all checklist. It's a locally calibrated, equity-centered approach that asks: What are the most urgent public health and climate concerns in this neighborhood? And how can this project become part of the solution? Two case studies from the book, one in the South Bronx and another in East London, show how this approach plays out in the real world. Toxic infrastructure to health-first housing The South Bronx is one of New York City's most environmentally burdened neighborhoods. Residents face compounding public health concerns, including high rates of obesity, diabetes, heart disease, and pediatric asthma—conditions tied directly to chronic exposure to air pollution, extreme heat, and poor housing conditions. Infrastructure like solid waste transfer stations, natural gas plants, and a daily flow of more than 750 diesel trucks has left a lasting environmental footprint. Three projects demonstrate how health-driven interventions play out in real life. Arbor House, a 124-unit LEED Platinum affordable housing development, took an indoor-focused strategy. With no regulatory leverage to reduce nearby traffic or emissions, the project team instead designed a protective shell: a high-performance building envelope, mechanical exhaust and ventilation systems, low-VOC materials, and a no-smoking policy. These features directly addressed local respiratory and cardiovascular risk data, providing a sanctuary of clean air in a polluted context. The Eltona, another LEED Platinum project by the same developer, built on these strategies but also benefited from its location within the Melrose Commons urban renewal zone. This area, guided by a community-authored plan, introduced pedestrian-prioritized streets and small green spaces to break up heat and pollution hot spots. This sort of coordinated planning can push health equity beyond the building envelope. The Peninsula represents an even bolder intervention: transforming a former juvenile detention center into a mixed-use anchor of community well-being. Once all phases are complete (anticipated in 2026), the project will deliver 740 units of affordable housing, a wellness center, daycare, supermarket, light industrial space, and a workforce development hub—all aligned with the long-standing Hunts Point Vision Plan. Created through a collaborative effort between local government and community groups, the plan calls for cleaner air, economic opportunity, and access to green space without displacing existing residents. This multiscalar transformation wouldn't have been possible without partnership. The development team committed to providing both affordable and middle-income housing, as well as commercial and industrial spaces aligned with local needs. The local government played a convening role, confronting outdated zoning and building codes to enable community-led regeneration. And community groups acted as watchdogs and visionaries—documenting health inequities, advocating for residents' needs, and ensuring decades of disinvestment didn't translate into displacement. From industrial blight to inclusive growth In East London's Hackney borough, Gillett Square shows how long-term, community-led urban design can build resilience without triggering displacement. Residents here also face elevated risks from exposure to traffic-related air pollution, unsafe pedestrian conditions, and mental health stressors, particularly among children and the elderly. Climate concerns such as extreme temperatures compound vulnerability, especially in a borough with high poverty rates and a large renter population. The project began in the 1980s as part of a broader, three-pronged effort to reduce crime, create economic opportunity for women- and minority-owned businesses, and preserve affordability in the face of rapidly rising property values. Organized by Hackney Co-operative Developments, a community interest company, this initiative has grown over 40 years into a model of place-based health equity. Unlike top-down redevelopment, the transformation of Gillett Square unfolded through continuous negotiation among residents, developers, and the local government. A former parking lot became the square itself. Adjacent buildings were renovated to create 30 affordable workspaces and 10 retail units prioritized for local startups and cultural groups. The existing street-facing storefronts remained intact, maintaining the character and economic rhythms of the block. During construction, current tenants were temporarily relocated—but not displaced—a rare feat in most urban redevelopment narratives. The built environment improvements weren't just aesthetic or economic. The renovated Bradbury Works building added insulation, operable windows, and improved ventilation to respond to extreme temperatures and indoor air quality concerns. It was also designed to accommodate a future rooftop solar array. Elsewhere on the square, an old factory became a jazz club. Another was converted into a mixed-use building with social housing and office space. Each adaptive reuse project layered with health-promoting elements such as natural light, passive ventilation, and energy efficiency. Importantly, these design moves responded to both immediate and long-term public health concerns identified in the architectural epidemiology framework: exposure to air pollution, heat vulnerability, mental health stressors, and pedestrian safety risks. The health situation analysis for the neighborhood emphasized the need for strategies that reduced the risk of obesity, mental health issues, and traffic-related injury, many of which were tackled by fine-grained, community-rooted design rather than by sweeping interventions. Gillett Square's evolution also depended on progressive land use policy and community engagement over time. The local government enabled critical rezonings: converting the parking lot into a plaza, allowing mixed-use development, and permitting the installation of small retail kiosks. The development team, operating as a nonprofit social enterprise, prioritized community interests. And community groups, many of which had been active in Hackney for decades, fought to ensure that the square's benefits didn't come at the expense of its existing residents. In a borough where 75% of residents are renters, and poverty rates among children and the elderly are among the highest in the U.K., the stakes of gentrification are high. Gillett Square proves that design can support resilience without fueling displacement—and that longevity, not speed, can be a hallmark of justice-oriented urban development. These case studies show that health equity can be the foundation, not a by-product, of urban development. By aligning investments with public health and climate data, Architectural Epidemiology offers a road map for building places that protect and uplift communities. This framework identifies community needs and guides community residents, developers, and designers to solutions that create value for both stakeholders and shareholders.
Globe and Mail
31-07-2025
- Business
- Globe and Mail
Merkel Cell Carcinoma Market is Expected to Advance at a CAGR of 8.7% Through 2034 as New Clinical Trials and Targeted Therapies Reshape Care
Merkel Cell Carcinoma Market Forecast, combines robust epidemiological data with market trends, competitive landscape analysis, and patient journey assessments. The report forecasts that the Merkel Cell Carcinoma (MCC) market in the 7MM. The Merkel Cell Carcinoma Market is expected to grow significantly in the 7MM, driven by the rising awareness among healthcare professionals contributing to earlier diagnosis, increasing chronic UV exposure, and the emergence of innovative therapies such as IFx-2.0 (TuHURA Biosciences), NIDLEGY (Philogen), MCLA 145 (Merus N.V.), ITI 3000 (Immunomic Therapeutics), PH 762 (Phio Pharmaceuticals / AgonOx), KT 253 (Kymera Therapeutics) and others. DelveInsight's latest report, ' Merkel Cell Carcinoma Market Insight, Epidemiology, and Market Forecast,' combines robust epidemiological data with market trends, competitive landscape analysis, and patient journey assessments. The report forecasts that the Merkel Cell Carcinoma (MCC) market in the 7MM which includes the United States, EU4 (Germany, France, Italy, and Spain), the United Kingdom, and Japan is expected to grow at a CAGR of 8.7% from USD 411 million between 2023 to 2034 Among the 7MM, the US market represented 44% of the total market size in 2023. Other major markets, EU4 and the UK, accounted for approximately 54%. Among the EU4 and the UK, Germany held the largest Merkel Cell Carcinoma market share, followed by France. Download the report to understand which factors are driving the Merkel Cell Carcinoma therapeutic market @ Merkel Cell Carcinoma Market Trends. The report also provides an in-depth epidemiological analysis and forecasts until 2034, segmented by Total Merkel Cell Carcinoma Incident Cases, Gender-specific Incident Cases, Stage-specific Incident Cases, Etiology-specific Incident Cases of Merkel Cell Carcinoma, and Total Metastatic Merkel Cell Carcinoma Cases in the 7MM. According to DelveInsight's analysis, there were approximately 9000 incident cases of MCC in the 7MM. Among them, the United States accounted for nearly 37% of the cases in 2023. Furthermore, in the EU4 and the UK, approximately 80% of the total reported cases are associated with MCPyV, while 20% are linked to UV damage, indicating that MCPyV is the primary causative factor. Discover evolving trends in Merkel Cell Carcinoma patient pool forecasts @ Merkel Cell Carcinoma Epidemiology Analysis Recent Developments: In July 2025, the National Comprehensive Cancer Network published updated guidelines for MCC treatment with several important changes, including ctDNA monitoring, Radiation timing, Hypo-fractionated radiation, and others. In June 2025, the FDA lifted a manufacturing-related partial clinical hold on the phase 3 accelerated approval trial for immune agonist IFx-2.0. The trial evaluates IFx-2.0 as adjunctive therapy versus placebo with pembrolizumab in frontline treatment for patients with advanced or metastatic MCC. In May 2025, a new clinical trial (NCT06940440) began evaluating the innate immune agonist IFx-Hu2.0 in patients with noncutaneous MCC of unknown primary. In January 2025, 225Ac-SSO110, a somatostatin receptor 2 (SST2) antagonist for targeted radionuclide cancer treatments of MCC developed by Ariceum Therapeutics, received clearance for a Phase 1/2 trial (SANTANA-225) and is expected to begin enrolling patients in the first quarter of 2025. In April 2025, a multicenter study of 1,049 Merkel Cell Carcinoma patients found that radiation within eight weeks of diagnosis improved survival and reduced disease progression risk by 36%. Surgical margins of 1-2 cm led to better outcomes. At five years, 83% of patients were alive and 64% had no cancer progression, highlighting the importance of timely treatment and appropriate surgery. The Delveinsight report also discusses current diagnosis and treatment strategies for Merkel Cell Carcinoma. Existing drugs for MCC treatment include KEYTRUDA (Merck), ZYNYZ (Incyte Corporation/MacroGenics), and BAVENCIO (Merck KGaA). The treatment depends on the disease stage and individual factors, primarily involving surgery as the first-line therapy, often combined with radiation or chemotherapy. Chemotherapy, once a key treatment for advanced Merkel Cell Carcinoma, now plays a reduced role due to limited long-term effectiveness. Cytotoxic chemotherapy, while it has been effective for metastatic MCC, often leads to significant side effects by affecting normal cells. DelveInsight's analysis reveals that several companies are launching clinical trials to investigate new MCC treatment options or to improve existing ones. The Merkel Cell Carcinoma clinical development pipeline includes drugs such as IFx-2.0 (TuHURA Biosciences), NIDLEGY (Philogen), MCLA 145 (Merus N.V.), ITI 3000 (Immunomic Therapeutics), PH 762 (Phio Pharmaceuticals/AgonOx), and KT 253 (Kymera Therapeutics), among others. Unlock which emerging Merkel Cell Carcinoma drug is expected to capture the largest market share in 7MM by 2034. Visit the Merkel Cell Carcinoma Market Insights. Another pipeline drug, IFx-2.0 (developed by TuHURA Biosciences), is also set for phase III trial with KEYTRUDA for advanced MCC in 2025. These developments highlight the momentum in the MCC treatment landscape. MCC presents significant challenges, especially in diagnosis, due to its rarity, unclear origin, and similarity to other skin lesions. DelveInsight's leading oncology consultant commented, 'As MCCs are frequently misdiagnosed, biomarkers are needed to improve their detection to prompt biopsy to confirm diagnosis by histology and immunohistochemistry, respectively.' This highlights the potential of more precise and sensitive emerging diagnostic methods to revolutionize Merkel Cell Carcinoma treatment, driving market growth. Table of Contents 1. Key Insights 2. Report Introduction 3. Merkel Cell Carcinoma Market Overview at a Glance 4. Executive Summary 5. Key Events 6. Merkel Cell Carcinoma Background and Overview 7. Merkel Cell Carcinoma Epidemiology and Market Methodology 8. Epidemiology and Merkel Cell Carcinoma Patient Population 9. Merkel Cell Carcinoma Patient Journey 10. Merkel Cell Carcinoma Marketed Therapies 11. Merkel Cell Carcinoma Emerging Drug Profiles 12. MCC: Market Analysis 13. Key Opinion Leaders' Views 14. Merkel Cell Carcinoma Unmet Needs 15. Merkel Cell Carcinoma SWOT Analysis 16. Merkel Cell Carcinoma Market Access and Reimbursement 17. Appendix 18. DelveInsight Capabilities 19. Disclaimer 20. About DelveInsight Merkel Cell Carcinoma Pipeline Insight Merkel Cell Carcinoma Pipeline Insight provides comprehensive insights about the Merkel Cell Carcinoma pipeline landscape, pipeline drug profiles, including clinical and non-clinical stage products, and the Merkel Cell Carcinoma companies, including ImmunityBio, OncoSec Medical, Exelixis, 4SC, Kartos therapeutics, Incyte corporation, Amgen, BioInvent International AB, SOTIO Biotech, Xencor, Exicure, Checkmate Pharmaceuticals, Takeda, Genocea Biosciences, NeoImmuneTech, and Sensei Biotherapeutics, among others. About DelveInsight DelveInsight is a leading business Healthcare consultancy and market research firm specializing in life sciences. It assists pharmaceutical companies by offering comprehensive, end-to-end solutions to improve their performance.
Globe and Mail
21-07-2025
- Health
- Globe and Mail
Sanofi, CSL Behring, ITB-Med LLC, Novo Nordisk A/S, Fortrea, Inc., Novartis, Afimmune, Pfizer, ADDMEDICA SASA
The Key Sickle Cell Disease Companies in the market include - Vertex Pharmaceuticals/CRISPR Therapeutics, Pfizer, Glycomimetics, Sanofi, CSL Behring, ITB-Med LLC, Novo Nordisk A/S, Fortrea, Inc., Novartis, Afimmune, Pfizer, ADDMEDICA SASA, CRISPR Therapeutics/Vertex Pharmaceuticals, Agios Pharmaceuticals, Alexion Pharmaceuticals, Chugai Pharmaceutical/Roche, Editas Medicine, Sangamo Therapeutics, Beam Therapeutics, CSL Behring, and others. DelveInsight's 'Sickle Cell Disease Market Insights, Epidemiology, and Market Forecast-2034″ report offers an in-depth understanding of the Sickle Cell Disease, historical and forecasted epidemiology as well as the Sickle Cell Disease market trends in the United States, EU4 (Germany, Spain, Italy, France) the United Kingdom. Some of the key facts of the Sickle Cell Disease Market Report: Among the 6MM countries the Sickle Cell Disease market size was valued ~USD 650 million in 2023 and is anticipated to grow with a significant CAGR during the study period (2020-2034) In May 2025, Beam Therapeutics Inc. (Nasdaq: BEAM), a biotechnology company specializing in precision genetic medicines via base editing, announced it will share new findings from its BEACON Phase 1/2 clinical trial of BEAM-101 at the upcoming European Hematology Association 2025 Congress (EHA2025), scheduled for June 12–15, 2025, in Milan, Italy. BEAM-101 is an investigational ex vivo genetically modified cell therapy being developed to treat sickle cell disease (SCD), specifically in patients experiencing severe vaso-occlusive crises (VOCs). In November 2024, BioLineRx Ltd. (NASDAQ: BLRX) (TASE: BLRX), a commercial-stage biopharmaceutical company focused on oncology and rare diseases, announced that an abstract featuring initial results from a Phase 1 trial of motixafortide—both as a monotherapy and in combination with natalizumab for CD34+ hematopoietic stem cell (HSC) mobilization in gene therapies for sickle cell disease (SCD)—has been accepted for oral presentation at the 66th American Society of Hematology (ASH) Annual Meeting & Exposition, taking place December 7-10, 2024, in San Diego, California. Conducted in collaboration with Washington University School of Medicine in St. Louis, this proof-of-concept study aims to explore alternative HSC mobilization approaches to enhance the treatment experience for SCD patients undergoing gene therapy. In June 2024, Vertex Pharmaceuticals shared long-term results for its gene therapy, Casgevy (exa-cel), in patients with sickle cell disease or transfusion-dependent beta-thalassemia (TDT). In 2023, the United States held the largest market share for Sickle Cell Disease among the 6MM, with approximately USD 603 million, followed by France and the UK. At present, treatments for Sickle Cell Disease include NSAIDs, blood transfusions, chelating agents, nutritional supplements, and broad-spectrum antibiotics. Additionally, the US FDA has approved several therapies for this condition, such as DROXIA (hydroxyurea), ENDARI (L-glutamine oral powder), ADAKVEO (crizanlizumab-tmca), and OXBRYTA (voxelotor). In 2023, the United States had the largest total number of prevalent Sickle Cell Disease cases among the 6MM. In the US, Sickle Cell Anemia (hemoglobin S/S or hemoglobin S/β0-thalassemia) was the most common subtype of Sickle Cell Disease among the type-specific prevalent cases in 2023. In the EU4 and the UK, France had the highest prevalence of Sickle Cell Disease cases, followed by the UK, while Spain reported the lowest number of cases. Key Sickle Cell Disease Companies: Vertex Pharmaceuticals/CRISPR Therapeutics, Pfizer, Glycomimetics, Sanofi, CSL Behring, ITB-Med LLC, Novo Nordisk A/S, Fortrea, Inc., Novartis, Afimmune, Pfizer, ADDMEDICA SASA, CRISPR Therapeutics/Vertex Pharmaceuticals, Agios Pharmaceuticals, Alexion Pharmaceuticals, Chugai Pharmaceutical/Roche, Editas Medicine, Sangamo Therapeutics, Beam Therapeutics, CSL Behring, and others Key Sickle Cell Disease Therapies: CASGEVY (exagamglogene autotemcel), Inclacumab, GMI-1687, BIVV003, CSL889, Siplizumab, Etavopivat Tablets, VIT-2763, Crizanlizumab, Epeleuton, Voxelotor, Hydroxycarbamide, Exagamglogene autotemcel, Mitapivat, Canakinumab, ALXN1820, Crovalimab, EDIT 301, BIVV003, BEAM101, Hemopexin, and others The Sickle Cell Disease epidemiology based on gender analyzed that Sickle Cell Disease affects males and females equally The Sickle Cell Disease market is expected to surge due to the disease's increasing prevalence and awareness during the forecast period. Furthermore, launching various multiple-stage Sickle Cell Disease pipeline products will significantly revolutionize the Sickle Cell Disease market dynamics. Sickle Cell Disease Overview Sickle cell disease (SCD) comprises inherited red blood cell disorders resulting from an abnormality in the structure of hemoglobin known as sickle hemoglobin (HbS), which encodes the beta hemoglobin subunit. Sickle Cell Disease Epidemiology The epidemiology section provides insights into the historical, current, and forecasted epidemiology trends in the seven major countries (7MM) from 2020 to 2034. It helps to recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. The epidemiology section also provides a detailed analysis of the diagnosed patient pool and future trends. Sickle Cell Disease Epidemiology Segmentation: The Sickle Cell Disease market report proffers epidemiological analysis for the study period 2020–2034 in the 7MM segmented into: Sickle Cell Disease Drugs Uptake and Pipeline Development Activities The drugs uptake section focuses on the rate of uptake of the potential drugs recently launched in the Sickle Cell Disease market or expected to get launched during the study period. The analysis covers Sickle Cell Disease market uptake by drugs, patient uptake by therapies, and sales of each drug. Moreover, the therapeutics assessment section helps understand the drugs with the most rapid uptake and the reasons behind the maximal use of the drugs. Additionally, it compares the drugs based on market share. The report also covers the Sickle Cell Disease Pipeline Development Activities. It provides valuable insights about different therapeutic candidates in various stages and the key companies involved in developing targeted therapeutics. It also analyzes recent developments such as collaborations, acquisitions, mergers, licensing patent details, and other information for emerging therapies. Sickle Cell Disease Therapies and Key Companies Discover more about therapies set to grab major Sickle Cell Disease market share @ Sickle Cell Disease Treatment Landscape Scope of the Sickle Cell Disease Market Report Study Period: 2020–2034 Coverage: 7MM [The United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom)] Key Sickle Cell Disease Companies: Vertex Pharmaceuticals/CRISPR Therapeutics, Pfizer, Glycomimetics, Sanofi, CSL Behring, ITB-Med LLC, Novo Nordisk A/S, Fortrea, Inc., Novartis, Afimmune, Pfizer, ADDMEDICA SASA, CRISPR Therapeutics/Vertex Pharmaceuticals, Agios Pharmaceuticals, Alexion Pharmaceuticals, Chugai Pharmaceutical/Roche, Editas Medicine, Sangamo Therapeutics, Beam Therapeutics, CSL Behring, and others Key Sickle Cell Disease Therapies: CASGEVY (exagamglogene autotemcel), Inclacumab, GMI-1687, BIVV003, CSL889, Siplizumab, Etavopivat Tablets, VIT-2763, Crizanlizumab, Epeleuton, Voxelotor, Hydroxycarbamide, Exagamglogene autotemcel, Mitapivat, Canakinumab, ALXN1820, Crovalimab, EDIT 301, BIVV003, BEAM101, Hemopexin, and others Sickle Cell Disease Therapeutic Assessment: Sickle Cell Disease current marketed and Sickle Cell Disease emerging therapies Sickle Cell Disease Market Dynamics: Sickle Cell Disease market drivers and Sickle Cell Disease market barriers Competitive Intelligence Analysis: SWOT analysis, PESTLE analysis, Porter's five forces, BCG Matrix, Market entry strategies Table of Contents 1. Sickle Cell Disease Market Report Introduction 2. Executive Summary for Sickle Cell Disease 3. SWOT analysis of Sickle Cell Disease 4. Sickle Cell Disease Patient Share (%) Overview at a Glance 5. Sickle Cell Disease Market Overview at a Glance 6. Sickle Cell Disease Disease Background and Overview 7. Sickle Cell Disease Epidemiology and Patient Population 8. Country-Specific Patient Population of Sickle Cell Disease 9. Sickle Cell Disease Current Treatment and Medical Practices 10. Sickle Cell Disease Unmet Needs 11. Sickle Cell Disease Emerging Therapies 12. Sickle Cell Disease Market Outlook 13. Country-Wise Sickle Cell Disease Market Analysis (2020–2034) 14. Sickle Cell Disease Market Access and Reimbursement of Therapies 15. Sickle Cell Disease Market Drivers 16. Sickle Cell Disease Market Barriers 17. Sickle Cell Disease Appendix 18. Sickle Cell Disease Report Methodology 19. DelveInsight Capabilities 20. Disclaimer 21. About DelveInsight About DelveInsight DelveInsight is a leading Healthcare Business Consultant, and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance. It also offers Healthcare Consulting Services, which benefits in market analysis to accelerate the business growth and overcome challenges with a practical approach. Media Contact Company Name: DelveInsight Contact Person: Gaurav Bora Email: Send Email Phone: +14699457679 Address: 304 S. Jones Blvd #2432 City: Albany State: New York Country: United States Website:
